Christopher Liu
Stock Analyst at Leerink Partners
(2.32)
# 2,387
Out of 4,789 analysts
5
Total ratings
50%
Success rate
14.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $2.47 | +628.74% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $14.77 | +82.80% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $68.00 | -38.24% | 1 | Aug 8, 2023 | |
| EXEL Exelixis | Initiates: Market Perform | $18 | $36.39 | -50.54% | 1 | Aug 8, 2023 |
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $2.47
Upside: +628.74%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $14.77
Upside: +82.80%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $68.00
Upside: -38.24%
Exelixis
Aug 8, 2023
Initiates: Market Perform
Price Target: $18
Current: $36.39
Upside: -50.54%